Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP). Patients with previously untreated histologically...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2009-11, Vol.27 (33), p.5513-5518
Hauptverfasser:	CUNNINGHAM, David, CHAU, Ian, FALK, Stephen, CRELLIN, Adrian, ADAB, Fawzi, THOMPSON, Joyce, LEONARD, Pauline, OSTROWSKI, Joe, EATOCH, Martin, SCHEITHAUER, Werner, HERRMANN, Richard, NEOPTOLEMOS, John P, STOCKEN, Deborah D, VALLE, Juan W, SMITH, David, STEWARD, William, HARPER, Peter G, DUNN, Janet, TUDUR-SMITH, Catrin, WEST, Julia
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Capecitabine Confidence Intervals Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Fluorouracil - analogs & derivatives Follow-Up Studies Gastroenterology. Liver. Pancreas. Abdomen Humans Infusions, Intravenous Kaplan-Meier Estimate Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Maximum Tolerated Dose Medical sciences Middle Aged Neoplasm Invasiveness - pathology Neoplasm Staging Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Probability Proportional Hazards Models Quality of Life Risk Assessment Statistics, Nonparametric Survival Analysis Time Factors Treatment Outcome Tumors United Kingdom
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP). Patients with previously untreated histologically or cytologically proven locally advanced or metastatic carcinoma of the pancreas with a performance status
ISSN:	0732-183X 1527-7755
DOI:	10.1200/JCO.2009.24.2446